30 results about "Methicillin sensitive" patented technology

Disclosed are methods of identifying a methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-sensitive Staphylococcus aureus (MSSA) in a sample. The present invention provides a diagnostic method comprising modification of sequences of S. aureus by converting non-methylated cytosine residues ultimately into thymidine residues in the target nucleic acid. The invention further provides for the detection of modified sequences derived from the spa gene, the mecA gene, and the integrated SCCmec cassette of S. aureus.

The invention provides a method for extracting a Staphylococcus aureus antigen which comprises using an extraction reagent with a pH of no higher than 5.0, containing one or more acids selected from among hydrochloric acid, acetic acid, citric acid, phosphoric acid, sulfuric acid and nitric acid, to extract a Staphylococcus aureus antigen comprising a methicillin-resistant Staphylococcus aureus antigen and / or a methicillin-sensitive Staphylococcus aureus antigen, from Staphylococcus aureus in a specimen. The invention further provides a method for assessing Staphylococcus aureus.

Disclosed are synthesized derivatives of a natural product, (±)-marinopyrrole A, shown as structural formula I, which have inhibition activities on gram-positive bacteria, such as methicillin sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), oxacilline-resistant Staphylococcus aureus (ORSA), methicillin-resistant Staphylococcus epidermidis (MRSE) and the like. Furthermore, the methods for preparing (±)-marinopyrrole A and the derivatives thereof are disclosed. According to the study of antibacterial activity in vitro, the synthesized derivatives of the natural product (±)-marinopyrrole A have excellent antibiotic activities on the gram-positive bacteria, such as methicillin sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), oxacilline-resistant Staphylococcus aureus (ORSA), methicillin-resistant Staphylococcus epidermidis (MRSE) and the like, and have potential prospects in clinical application.

The invention discloses a cephalosporins compound and pharmaceutically acceptable salt thereof, preparation methods of the compounds, a pharmaceutical composition comprising the compounds or the salt thereof, and applications in preparing the pharmaceutics for treating and / or preventing infectious diseases. The cephalosporins compound has a good bacteriostatic activity to gram-positive bacteria such as MRSA (Methicillin-resistant Staphylococcus aureus), MSSA (Methicillin Sensitive Staphylococcus Aureus) and MRSE (Methicillin Resistant Staphylococcus Epidermidis), and gram-negative bacteria such as drug-resistant bacteria producing ESBLs (Extended Spectyum beta Lactamase), is wide in antibacterial spectrum, strong in antibacterial activity, low-toxicity, and anti-drug resistance, thereby having extremely high research and development values.

The invention provides a composition used for detection of methicillin-resistant and / or tetracycline-resistant staphylococcus aureus. The composition used for detection of the methicillin-resistant and / or tetracycline-resistant staphylococcus aureus comprises a primer pair shown in SEQ ID No.1 / 2 and at least one of primer pairs shown in SEQ ID NO.3 / 4 and SEQ ID NO.5 / 6; meanwhile, an mPCR-DHPLC / electrophoresis detection kit and method are further constructed on the basis, and pathogenic staphylococcus aureus, MRSA and tetracycline-resistant staphylococcus aureus drug resistant strains in food are detected; and bacterial strain identification is carried out on staphylococcus aureus by utilizing the composition and the method which are disclosed by the invention, and MRSA and a tetracycline-resistant gene can be detected at the same time, so that staphylococcus aureus, MRSA and erythromycin-resistant staphylococcus aureus in a sample can be identified at the same time during one-step detection. The composition used for detection of methicillin-resistant and / or tetracycline-resistant staphylococcus aureus has the advantages of high speed and high throughput; and meanwhile, detection time is short, operation is simple, labour and cost can be greatly saved, and the rapid detection requirement can be met.

The invention discloses application of a 4-oxo-2-crotonamide derivative to preparation of bacteriostatic agents. The structure of the 4-oxo-2-crotonamide derivative is shown as a formula (I). The 4-oxo-2-crotonamide derivative has a bacteriostatic effect; good antibacterial activity can be realized on methicillin-resistant staphylococcus aureus, methicillin-resistant staphylococcus epidermidis, vancomycin drug-resistant enterococcus faecalis, vancomycin drug-resistant enterococcus faecium, methicillin-sensitive staphylococcus aureus, methicillin-sensitive staphylococcus epidermidis, vancomycin-sensitive enterococcus faecalis and vancomycin-sensitive enterococcus faecium. The formula I is shown in the description.

The present invention discloses a lysin that is capable of killing Staphylococcus and the use thereof, belonging to the field of biological agents. The present invention discloses the amino acid sequence and the encoding gene sequence of the lysin. This lysin keeps active in a wide range of pH. It has lytic activity against Staphylococcus in pH 4-11. The recombinant protease constructed by the encoding gene can be solubly expressed in E. coli strain BL21 (DE3). The lysin can be used to effectively kill multiple species Staphylococcus in vitro, including methicillin sensitive Staphylococcus aureus (MSSA) and methicillin resistant Staphylococcus aureus (MRSA) isolated in clinics. This lysin can be used as an antibiotic for the treatment of staphylococcal infections in vivo. This lysin is also able to rapidly lyse staphylococcal cell wall; as a result, intracellular substances such as ATP and DNA are released. Those released substances can be used to detect the type of Staphylococcus.

The invention discloses a methacycline derivative with remarkable antimicrobial activity. The methacycline derivative has the following structure: FORMULA (I), which has good very good antibacterial action on meticillin resistant staphylococcus aureus (MRSA) and methicillin-sensitive staphylococcus aureus (MSSA).

The invention provides a composition used for detection of methicillin-resistant and / or tetracycline-resistant staphylococcus aureus. The composition used for detection of the methicillin-resistant and / or tetracycline-resistant staphylococcus aureus comprises a primer pair shown in SEQ ID No.1 / 2 and at least one of primer pairs shown in SEQ ID NO.3 / 4 and SEQ ID NO.5 / 6; meanwhile, an mPCR-DHPLC / electrophoresis detection kit and method are further constructed on the basis, and pathogenic staphylococcus aureus, MRSA and tetracycline-resistant staphylococcus aureus drug resistant strains in food are detected; and bacterial strain identification is carried out on staphylococcus aureus by utilizing the composition and the method which are disclosed by the invention, and MRSA and a tetracycline-resistant gene can be detected at the same time, so that staphylococcus aureus, MRSA and erythromycin-resistant staphylococcus aureus in a sample can be identified at the same time during one-step detection. The composition used for detection of methicillin-resistant and / or tetracycline-resistant staphylococcus aureus has the advantages of high speed and high throughput; and meanwhile, detection time is short, operation is simple, labour and cost can be greatly saved, and the rapid detection requirement can be met.

The present invention relates to a biodegradable, inhalable microparticle formulation comprising a compound of formula I obtained by fermentation of a microorganism of the Streptomyces species (PM0626271 / MTCC5447), as described in PCT application publication WO2011027290, and a biodegradable lipid for drug delivery wherein the ratio of drug (compound of formula I) to lipid is 1:15 to 1:25. The present invention also relates to the process for preparation of the formulation and to the method of treatment of pulmonary tuberculosis, multi drug resistant tuberculosis (MDRTB), methicillin resistant Staphylococcus aureus (MRSA) pneumonias and methicillin sensitive Staphylococcus aureus (MSSA) pneumonias by administering therapeutically effective amount of the formulation to a mammal in need thereof. The present invention further relates to a method of delivering the microparticle formulation to a mammal in need thereof, wherein the formulation is administered by inhalation or intratracheal instillation for pulmonary delivery.

The invention relates to a new compound with significant antibacterial activity, the structure is as follows: (formula I), and the new compound has great antibacterial effect for methicillin resistant Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus (MSSA). (Formula I).

The invention belongs to the technical field of medicines and discloses a structure of an antidiarrheal ligan compound A with natural bacteriostatic activity and application of the antidiarrheal ligan compound A to bacteriostasis. In-vitro culture screening experiments and in-vitro bacteriostatic activity tests show that the antidiarrheal ligan compound A has a relatively obvious inhibitory activity on two selected bacteriostatic strains. The specific data is that the antidiarrheal ligan compound A has an extremely strong inhibitory effect on methicillin-sensitive staphylococcus aureus, and the MIC (Minimal Inhibitory Concentration) is 128 [mu]g / mL; the antidiarrheal ligan compound A also has an extremely strong inhibitory effect on methicillin-resistant and vancomycin-resistant staphylocccus aureus, and the MIC value is 128 [mu]g / mL.

Method of detecting methicillin-resistant S. aureus (MRSA) and methicillin-sensitive S. aureus (MSSA) in a nucleic acid coamplification assay. The invention advantageously reduces the incidence of false-positive MRSA determinations in real-time assays by requiring satisfaction of a threshold criterion that excludes certain co-infections from the MRSA determination. The invention further provides for determination of MSSA, even when the MSSA is present in combination with methicillin-resistant coagulase-negative (MR-CoNS) bacteria at high or low levels.